文献速递神经肿瘤

脑膜瘤多平台分子谱分析为分子机制提供见解并优先排序药物靶点以支持合理临床试验设计

Multiplatform profiling of meningioma provides molecular insight and prioritization of drug targets for rational clinical trial design.
PubMed 文献 · J Neurooncol · 2018-05-30

该研究对115例脑膜瘤进行多平台分子谱分析,采用二代测序、免疫组化和原位杂交检测突变与表达状态。结果显示NF2突变最常见(85%,11/13),TOP2A和胸苷酸合成酶表达随级别升高而增加,孕激素受体表达随级别降低。作者认为基于肿瘤表达,针对NF2和TOP2A的疗法可考虑用于多数脑膜瘤患者。

要点

  • NF2突变在所有级别脑膜瘤中最常见,频率为85%(11/13)。
  • TOP2A和胸苷酸合成酶表达随级别升高而增加(I=5%、II=22%、III=62%;I=5%、II=23%、III=47%)。
  • 孕激素受体表达随级别降低(I=79%、II=41%、III=29%)。

核心结论

  • 若基于肿瘤表达,作者认为针对NF2和TOP2A的疗法可考虑用于多数脑膜瘤患者。

研究设计与样本

  • 对115例脑膜瘤采用多种策略进行分子谱分析,包括二代测序(592基因 panel:n=14;47基因 panel:n=94)、免疫组化(n=8-110)和荧光及显色原位杂交(n=5-70)。

主要发现

  • 患者中位年龄60岁,范围6-90岁;52%为女性。
  • 最常表达的蛋白标志物为EGFR(93%;n=44),其次为PTEN(77%;n=110)、BCRP(75%;n=8)、MRP1(65%,n=23)、PGP(62%;n=84)和MGMT(55%;n=97)。
  • 所有级别脑膜瘤中最常见的突变为NF2基因,频率85%(11/13);SMO和AKT1重复突变偶有检测到。
  • PD-L1在25%的III级病例中表达(2/8),在I或II级肿瘤中不表达;PD-1+ T细胞存在于46%(24/52)的脑膜瘤中。
  • TOP2A和胸苷酸合成酶表达随级别升高而增加(分别为I=5%、II=22%、III=62%和I=5%、II=23%、III=47%),而孕激素受体表达随级别降低(I=79%、II=41%、III=29%)。

临床怎么用

  • 作者认为,若基于肿瘤表达,针对NF2和TOP2A的疗法可考虑用于多数脑膜瘤患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Surgery and radiation therapy are the standard treatment options for meningiomas, but these treatments are not always feasible. Expression profiling was performed to determine the presence of therapeutic actionable biomarkers for prioritization and selection of agents. METHODS: Meningiomas (n = 115) were profiled using a variety of strategies including next-generation sequencing (592-gene panel: n = 14; 47-gene panel: n = 94), immunohistochemistry (n = 8-110), and fluorescent and chromogenic in situ hybridization (n = 5-70) to determine mutational and expression status. RESULTS: The median age of patients in the cohort was 60 years, with a range spanning 6-90 years; 52% were female. The most frequently expressed protein markers were EGFR (93%; n = 44), followed by PTEN (77%; n = 110), BCRP (75%; n = 8), MRP1 (65%, n = 23), PGP (62%; n = 84), and MGMT (55%; n = 97). The most frequent mutation among all meningioma grades occurred in the NF2 gene at 85% (11/13). Recurring mutations in SMO and AKT1 were also occasionally detected. PD-L1 was expressed in 25% of grade III cases (2/8) but not in grade I or II tumors. PD-1 + T cells were present in 46% (24/52) of meningiomas. TOP2A and thymidylate synthase expression increased with grade (I = 5%, II = 22%, III = 62% and I = 5%, II = 23%, III = 47%, respectively), whereas progesterone receptor expression decreased with grade (I = 79%, II = 41%, III = 29%). CONCLUSION: If predicated on tumor expression, our data suggest that therapeutics directed toward NF2 and TOP2A could be considered for most meningioma patients.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Everson RG, Hashimoto Y, Freeman JL, et al. Multiplatform profiling of meningioma provides molecular insight and prioritization of drug targets for rational clinical trial design. J Neurooncol. 2018. PMID: 29846894. doi:10.1007/s11060-018-2891-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。